Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 1;34(2):193-196.
doi: 10.1016/j.cmet.2022.01.002.

From the dish to humans: A stem cell recipe for success

Holger A Russ  1 , Ali H Shilleh  1 , Lori Sussel  2
Affiliations
Comment

From the dish to humans: A stem cell recipe for success

Holger A Russ et al. Cell Metab. .

Abstract

Islet transplantation has proven to be an effective treatment for type 1 diabetes (T1D) yet is hampered by the shortage of available tissue. Recently, two reports from a Viacyte multicenter clinical trial demonstrate the feasibility, safety, and potential efficacy of transplanting macro-encapsulated human stem cell-derived pancreatic endoderm cells into patients with T1D, highlighting the promise of a stem cell-based therapeutic approach.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.A.R. is an SAB member at Sigilon Therapeutics and Prellis Biologics and consultant to Eli Lilly and Minutia. H.A.R. has filed patent applications in the research space.

Figures

Figure 1.
Figure 1.. Current and potential stem cell-based therapeutic strategies for T1D treatment
Transplantation of pancreatic endoderm cells (PECs) and stem cell-derived beta-like cells into preclinical animal models has demonstrated the ability to successfully reverse diabetes, albeit with caveats associated with each approach. Recently, results from a multi-center clinical trial (NCT03163511) provided preliminary results showing the feasibility of using encapsulated stem cell-derived PECs as replacement therapy for patients suffering from T1D. A combined phase 1/2 clinical trial (NCT04786262) is also ongoing and awaits dissemination of peer-reviewed results.
See this image and copyright information in PMC

Comment on

References

    1. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, et al. (2012). Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care 35, 1436–1445. - PMC - PubMed
    1. Castro-Gutierrez R, Alkanani A, Mathews CE, Michels A, and Russ HA (2021). Protecting Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic T Cell Recognition. Front. Endocrinol. (Lausanne) 12, 707881. - PMC - PubMed
    1. D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, and Baetge EE (2006). Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat. Biotechnol. 24, 1392–1401. - PubMed
    1. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26, 443–452. - PubMed
    1. Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, and Melton DA (2014). Generation of functional human pancreatic β cells in vitro. Cell 159, 428–439. - PMC - PubMed

Publication types